Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  08/17/2006
 
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  001-15281
 
Delaware
  
76-0233274
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal executive offices, including zip code)
 
(281) 719-3400
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Information to be included in the report

 
Item 8.01.    Other Events
 
In a press release dated August 17, 2006, Repros Therapeutics Inc. announced that it will commence trading on the NASDAQ Global Market beginning at the open of trading on Monday, August 21, 2006. Repros' shares will continue to be traded under the ticker RPRX on the NASDAQ Global Market.

A copy of the Company's press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

 
 
Item 9.01.    Financial Statements and Exhibits
 
c. Exhibits

Exhibit

Number          Description
------          -----------
99.1            Press Release dated August 17, 2006.
 

 

Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
      
 
Repros Therapeutics Inc.
 
 
Date: August 18, 2006
     
By:
 
/s/    Louis Ploth, Jr.
               
Louis Ploth, Jr.
               
Vice President, Business Development, Chief Financial Officer and Secretary
 
 

 

Exhibit Index
 
Exhibit No.
  
Description
EX-99.1
  
Press Release dated August 17, 2006.